FDA Seems Unlikely To Move Hydrocodone To Stricter Class

Law360, New York (October 31, 2012, 8:18 PM EDT) -- A key U.S. Food and Drug Administration official appeared to be leaning against recommending that hydrocodone-based painkillers be reclassified to a more restrictive drug schedule, according to new documents — a good sign for drugmakers and pharmacists who oppose up-scheduling.

The FDA released the documents last Thursday, ahead of a scheduled meeting looking at whether to change the Controlled Substances Act classification for hydrocodone combination products from Schedule III to the more restrictive Schedule II.

Hydrocodone products, such as Abbott Laboratories' Vicodin, are some of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.